Renewal of the marketing authorization for Sibnayal® in the European Union

Advicenne, a pharmaceutical company specializing in the treatment of rare kidney diseases, announces the renewal of the Marketing Authorization (MA) for its flagship product, Sibnayal®. This medication, intended for the treatment of distal renal tubular acidosis, has received approval from the European Medicines Agency effective January 2026. This renewal marks a key milestone for the continued development of the product in Europe.

In addition to this validation in Europe, Advicenne recently obtained a marketing authorization in Saudi Arabia and has filed a registration application with the Food & Drug Administration in the United States, signifying potential expansion into various global markets for Sibnayal®.